Stock Track | Neogen Corp Plummets 5.06% After Disappointing Q3 Results and Widening Losses

Stock Track
11 Apr

Neogen Corporation (NASDAQ:NEOG) saw its stock price plummet by 5.06% in Friday's trading session, following the release of its disappointing third-quarter 2025 financial results. The food safety and animal health company's shares have been under significant pressure, with this latest drop adding to a series of setbacks for investors.

The company reported a net loss of $11 million for Q3 2025, a stark 442% increase from the loss in the same quarter last year. Revenue also declined by 3.4% to $221 million, falling short of analyst expectations by 1.5%. Neogen's earnings per share deteriorated further to a loss of $0.05, missing analyst estimates by 200% and deepening from the $0.009 loss per share in Q3 2024.

This poor quarterly performance comes amid a broader downturn for Neogen, with the stock having lost a staggering 83% of its value over the past five years. The company's struggles are further highlighted by a 57% decline in share price over the past year alone, with a 31% drop recorded just in the past week. Investors are growing increasingly concerned about Neogen's ability to return to profitability, especially as the company faces challenges in both its top and bottom lines. As the market digests these results, the outlook for Neogen remains uncertain, with analysts forecasting modest revenue growth of 2.5% per annum over the next three years, significantly below the 7.8% growth projected for the US Medical Equipment industry as a whole.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10